Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer

NCT00875264 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00875264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00875264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
Lead sponsor
Cephalon
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2007
Completion date
June 30, 2011
Enrollment
43 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer